Table 4.

Immunohistochemical analysis of prostatic tissue markers

P
Degarelix (A)Degarelix + bicalutamide (B)LHRH agonist + bicalutamide (C)OverallaA vs. BbA vs. CbB vs. Cb
n = 12n = 12n = 11
PSA positivity, n (%)c12 (100)12 (100)11 (100)0.824
PSAP positivity, n (%)c12 (100)12 (100)11 (100)0.824
AR positivity, n (%)c12 (100)12 (100)11 (100)0.824
Mean Ki67 (range)2.38 (0.00–8.00)1.27 (0.00–5.50)0.39 (0.00–1.50)0.2070.2250.0650.359
Mean CD56 (range)10.70 (0.00–57.00)10.36 (0.00–50.00)18.67 (0.00–60.00)0.8570.9400.7630.509
Mean CGA (range)38.75 (0.00–100.00)54.00 (0.00–100.00)28.82 (0.00–100.00)0.9710.9630.8960.769
Mean SYP (range)19.58 (0.00–72.00)16.55 (0.00–67.00)9.09 (0.00–50.00)0.8620.8810.7150.567
Mean AMACR (range)87.27 (50.00–10.00)56.64 (0.00–100.00)43.91 (0.00–100.00)0.0830.1720.0120.419
  • Abbreviations: AMACR, alpha-methylacyl-CoA racemase; CD56, cluster of differentiation 56; CGA, chromogranin A; PSAP, prostate-specific acid phosphatase; SYP, synaptophysin.

  • aKruskall–Wallis H test.

  • bMann–Whitney test.

  • cStains for PSA, PSA, and AR were all of the same intensity in all patients.